Iovance receives FDA clearance for IL-12 tethered TIL therapy trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
- Oil prices fall to seven-week low as Iran and Israel halt attacks
- Micron to deliver 'another strong quarter', Goldman says
- Potential implications from SpaceX IPO for Tesla?
- TSMC falls as Taiwan mulls curbs on AI chip exports to China
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- UK's Ofcom requires tech firms to create crisis response plans
- Supermicro plans $7 billion financing to fund AI server orders
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
June 1, 2026 7:30 AM EDTNext-Generation Platform Expands into Solid TumorsÂ
Representing 100,000+ U.S. Deaths Annually
SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced allowance to proceed from the U.S. Food and Drug Administration (FDA) for the investigational new drug (IND) application for a Phase 1/2 basket trial of IOV-5001, a next-generation interleukin-12 (IL-12) tethered TIL therapy.
The Phase 1/2 trial will begin... More
